• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by CorMedix Inc.

    2/14/22 4:33:01 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRMD alert in real time by email
    SC 13G 1 tm226647d2_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. __)*

     

    CorMedix Inc.

    (Name of Issuer)

     

    Common stock, $0.001 par value

    (Title of Class of Securities)

     

    21900C308

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      x Rule 13d-1(b)
         
      ¨ Rule 13d-1(c)
         
      ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 21900C308 13G Page 2 of 9 Pages

     

    1.

    Names of Reporting Persons

     

    Nomura Holdings, Inc.

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)  ¨
      (b)  ¨
    3. SEC Use Only
    4. Citizenship or Place of Organization:  Japan

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With
    5. Sole Voting Power     0

     

    6. Shared Voting Power   2,003,612 (1)

     

    7. Sole Dispositive Power 0

     

    8. Shared Dispositive Power 2,003,612 (1)

    9. Aggregate Amount Beneficially Owned by Each Reporting Person   
      2,003,612
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
      Not applicable
    11. Percent of Class Represented by Amount in Row (9)  
      5.3% (2)
    12. Type of Reporting Person (See Instructions)
      HC

     

    (1)This represents 2,003,612 shares beneficially owned by Nomura Global Financial Products, Inc. (“NGFP”). NGFP is a wholly owned subsidiary of Nomura Holdings, Inc., which accordingly may be deemed to beneficially own the shares beneficially owned by NGFP.

     

    (2)The percent of class is calculated based on 38,086,437 shares of common stock issued and outstanding as of November 5, 2021 as reported in the Issuer’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2021 filed with the SEC on November 9, 2021.

     

     

     

     

    CUSIP No. 21900C308 13G Page 3 of 9 Pages

     

    1.

    Names of Reporting Persons

     

    Nomura Global Financial Products, Inc.

    2. Check the Appropriate Box if a Member of a Group (See Instructions)
      (a)  ¨
      (b)  ¨
    3. SEC Use Only
    4. Citizenship or Place of Organization:  Delaware

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With
    5. Sole Voting Power     0

     

    6. Shared Voting Power   2,003,612

     

    7. Sole Dispositive Power 0

     

    8. Shared Dispositive Power 2,003,612

    9. Aggregate Amount Beneficially Owned by Each Reporting Person   
      2,003,612
    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
      Not applicable
    11. Percent of Class Represented by Amount in Row (9)  
      5.3% (3)
    12. Type of Reporting Person (See Instructions)
      BD

     

    (3)The percent of class is calculated based on 38,086,437 shares of common stock issued and outstanding as of November 5, 2021 as reported in the Issuer’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2021 filed with the SEC on November 9, 2021.

     

     

     

    CUSIP No. 21900C308 13G Page 4 of 9 Pages

     

    Item 1. (a)

    Name of Issuer:

     

    CorMedix Inc.

         
      (b)

    Address of Issuer's Principal Executive Offices:

     

    300 Connell Drive, Suite 4200

    Berkeley Heights, NJ 07922

     
    Item 2. (a)

    Name of Person(s) Filing:

    Nomura Holdings, Inc.

    Nomura Global Financial Products, Inc.

         
      (b)

    Address of Principal Business Office or, if none, Residence:
    Nomura Holdings, Inc.

    13-1, Nihonbashi 1-chome, Chuo-ku, Tokyo 103-8645, Japan

     

    Nomura Global Financial Products, Inc.

    Worldwide Plaza

    309 West 49th Street

    New York, NY 10019

         
      (c)

    Citizenship:
    Nomura Holdings, Inc.

    Japan

     

    Nomura Global Financial Products, Inc.

    Delaware

         
      (d)

    Title of Class of Securities:

     

    Common Stock, par value $0.001

         
      (e)

    CUSIP Number:

     

    21900C308

     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      (a) x Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ¨  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
      (k) ¨

    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________

     

     

     

    CUSIP No. 21900C308 13G Page 5 of 9 Pages

     

    Item 4.

    Ownership.

     

      Items 5-11 of the cover page are incorporated by reference
     
    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.
       
    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     
    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    See Exhibit B

     

    Item 8.

    Identification and Classification of Members of the Group.

     

    Not applicable

     
    Item 9.

    Notice of Dissolution of Group.

     

    Not applicable

     

     

     

     

    CUSIP No. 21900C308 13G Page 6 of 9 Pages

     

    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    SIGNATURE

     

    After reasonable inquiry and to the best of the knowledge and belief of the undersigned, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    EXECUTED as a sealed instrument this 14th day of February, 2022.

     

      Nomura Holdings, Inc.
       
      /s/ Samir Patel
      Name: Samir Patel
      Title: Managing Director
       
      Nomura Global Financial Products, Inc.
       
      /s/ Samir Patel
      Name: Samir Patel
      Title: Authorized Officer

     

     

     

     

    CUSIP No. 21900C308 13G Page 7 of 9 Pages

     

    Index to Exhibits

     

    Exhibit   Exhibit
    A      Joint Filing Agreement
    B        Subsidiaries

     

     

     

     

    CUSIP No. 21900C308 13G Page 8 of 9 Pages

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, the persons or entities named below agree to the joint filing on behalf of each of them of this Schedule 13G with respect to the Securities of the Issuer and further agree that this Joint Filing Agreement be included as an exhibit to this Schedule 13G. In evidence thereof, the undersigned hereby execute this Joint Filing Agreement as of February 14, 2022.

     

    Nomura Holdings, Inc.  
       
    /s/ Samir Patel  
    Name: Samir Patel  
    Title: Managing Director  
       
    Nomura Global Financial Products, Inc.  
       
    /s/ Samir Patel  
    Name: Samir Patel  
    Title: Authorized Officer  

     

     

     

     

    CUSIP No. 21900C308 13G Page 9 of 9 Pages

     

    EXHIBIT B

     

    SUBSIDIARIES

     

    Nomura Global Financial Products, Inc. is a wholly owned subsidiary of Nomura Holdings, Inc.

     

     

     

     

    Get the next $CRMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRMD

    DatePrice TargetRatingAnalyst
    3/7/2025$18.00Outperform
    Leerink Partners
    1/13/2025$15.00Buy
    D. Boral Capital
    8/26/2024$13.00Buy
    Rodman & Renshaw
    8/10/2023$6.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $CRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Cormedix with a new price target

      Leerink Partners initiated coverage of Cormedix with a rating of Outperform and set a new price target of $18.00

      3/7/25 7:21:39 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • D. Boral Capital initiated coverage on Cormedix with a new price target

      D. Boral Capital initiated coverage of Cormedix with a rating of Buy and set a new price target of $15.00

      1/13/25 8:29:07 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Cormedix with a new price target

      Rodman & Renshaw initiated coverage of Cormedix with a rating of Buy and set a new price target of $13.00

      8/26/24 7:31:35 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 17, 2023 - FDA Roundup: November 17, 2023

      For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation

      11/17/23 4:18:44 PM ET
      $BMY
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for DEFENCATH issued to CORMEDIX INC

      Submission status for CORMEDIX INC's drug DEFENCATH (ORIG-1) with active ingredient TAUROLIDINE AND HEPARIN SODIUM has changed to 'Approval' on 11/15/2023. Application Category: NDA, Application Number: 214520, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

      11/15/23 9:53:06 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    SEC Filings

    See more
    • SEC Form 10-Q filed by CorMedix Inc.

      10-Q - CorMedix Inc. (0001410098) (Filer)

      5/6/25 8:32:06 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CorMedix Inc. (0001410098) (Filer)

      5/6/25 7:45:34 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by CorMedix Inc.

      DEFA14A - CorMedix Inc. (0001410098) (Filer)

      4/28/25 4:31:37 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Commercial Officer Mistry Erin bought $14,985 worth of shares (1,500 units at $9.99), increasing direct ownership by 3% to 52,011 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      12/13/24 4:15:22 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Todisco Joseph bought $50,718 worth of shares (13,561 units at $3.74), increasing direct ownership by 4% to 352,839 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      3/14/24 8:45:21 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dunton Alan W bought $20,250 worth of shares (6,000 units at $3.38), increasing direct ownership by 65% to 15,250 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      12/18/23 4:47:41 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CRMD
    Leadership Updates

    Live Leadership Updates

    See more

    $CRMD
    Financials

    Live finance-specific insights

    See more
    • CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

      ‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces net sales of $39.1 million for the first quarter of 2025, largely driven by successful implementation by its outpatient dialys

      5/6/25 7:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

      BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, May 6th @ 8:30am ETDomestic:1-844-676-2922International:1-412-634-6840Conference ID:10198548Webcast:Webcast Link   About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic pr

      4/29/25 8:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

      ‒ Q1 2025 Unaudited Net Revenue of $39.0 million ‒ ‒ Expected Q1 Adjusted EBITDA above $22.5 million ‒ ‒ Q1 2025 Cash and Cash Equivalents of Approximately $77.5 million ‒ BERKELEY HEIGHTS, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces its preliminary unaudited first quarter results and provides an update on its business. These include the following key updates: CorMedix announces preliminary, unaudited net revenue of $39.0 million for 1Q 2025, and expects 1Q 2025 adjusted EBITDA(1) to exceed $22

      4/8/25 7:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. Announces Appointment of Chief Legal Officer

      BERKELEY HEIGHTS, N.J., Dec. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the appointment of Beth Zelnick Kaufman, Esq. as EVP, Chief Legal Officer, and Corporate Secretary, effective December 12, 2023. The Company also announced that, upon mutual agreement with the Company, Dr. Phoebe Mounts will no longer serve as the Company's General Counsel, effective December 12, 2023, and will be separating from CorMedix effective December 31, 2023, to pursue other opportunities. Ms. Zelnick Kaufman has

      12/15/23 8:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. Announces Partnership With The Leapfrog Group

      – CorMedix to advocate for patient safety and infection prevention as part of Leapfrog's Partners Advisory Committee BERKELEY HEIGHTS, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced an agreement with The Leapfrog Group, an independent national watchdog organization of employers and other purchasers focused on health care safety, whereby CorMedix Inc. will become a member of the Leapfrog Partners Advisory Committee. The Partners Advisory Committee is a platform for the crea

      12/4/23 8:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cormedix Inc. Announces Appointment of Robert A. Stewart to Its Board of Directors

      BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the appointment of Robert A. Stewart to the CorMedix Board of Directors. Following the appointment of Mr. Stewart, the Board will comprise 8 directors, 7 of which are independent. "We are pleased to welcome Rob Stewart to the CorMedix Board," said Joseph Todisco, Chief Executive Officer of CorMedix. "Rob's deep experience in global pharmaceutical management and broad professional network in the pharma space will be inval

      4/17/23 8:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

      ‒ Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, NJ., May 06, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the first quarter ended March 31, 2025 and provided an update on its business. Recent Corporate Highlights: CorMedix announces net sales of $39.1 million for the first quarter of 2025, largely driven by successful implementation by its outpatient dialys

      5/6/25 7:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

      BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, May 6th @ 8:30am ETDomestic:1-844-676-2922International:1-412-634-6840Conference ID:10198548Webcast:Webcast Link   About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic pr

      4/29/25 8:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      ‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided an update on its business. Recent Corporate Highlights: CorMedix today reports its second full quarter of DefenCath sales since commencing outpatient launch in

      3/25/25 7:30:00 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CorMedix Inc.

      SC 13G/A - CorMedix Inc. (0001410098) (Subject)

      11/14/24 4:34:05 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by CorMedix Inc. (Amendment)

      SC 13G/A - CorMedix Inc. (0001410098) (Subject)

      2/14/24 10:37:21 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by CorMedix Inc.

      SC 13G - CorMedix Inc. (0001410098) (Subject)

      2/13/24 5:02:29 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lefkowitz Steven W exercised 20,000 shares at a strike of $4.03, increasing direct ownership by 20% to 120,498 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      4/3/25 4:30:05 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Todisco Joseph exercised 59,170 shares at a strike of $3.38, increasing direct ownership by 13% to 530,721 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      4/2/25 7:00:03 AM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Todisco Joseph was granted 187,500 shares and covered exercise/tax liability with 23,977 shares, increasing direct ownership by 53% to 471,551 units (SEC Form 4)

      4 - CorMedix Inc. (0001410098) (Issuer)

      1/22/25 9:11:40 PM ET
      $CRMD
      Biotechnology: Pharmaceutical Preparations
      Health Care